Perhaps most importantly, our work, in the context of preclinical studies from other groups, supports the contribution of IL-1-mediated inflammation to osteosarcoma metastasis, and this finding justifies a clinical trial of IL-1 blockade to prevent metastatic recurrence in these patients. The gene discussed is IL1A; the disease is osteosarcoma.